Inhibitors and PROTACs of CDK2: challenges and opportunities.

Autor:	Zeng Y; Medical College, Guizhou University, Guiyang, China., Ren X; Medical College, Guizhou University, Guiyang, China., Jin P; Medical College, Guizhou University, Guiyang, China., Fan Z; Medical College, Guizhou University, Guiyang, China., Liu M; Medical College, Guizhou University, Guiyang, China., Zhang Y; Medical College, Guizhou University, Guiyang, China., Li L; Medical College, Guizhou University, Guiyang, China., Zhuo M; Medical College, Guizhou University, Guiyang, China., Wang J; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, China., Li Z; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, China., Wu M; Department of Neurosurgery, Guizhou Provincial People's Hospital, Guiyang, China.
Jazyk:	angličtina
Zdroj:	Expert opinion on drug discovery [Expert Opin Drug Discov] 2024 Sep; Vol. 19 (9), pp. 1125-1148. Date of Electronic Publication: 2024 Jul 12.
DOI:	10.1080/17460441.2024.2376655
Abstrakt:	Introduction: Abundant evidence suggests that the overexpression of CDK2-cyclin A/E complex disrupts normal cell cycle regulation, leading to uncontrolled proliferation of cancer cells. Thus, CDK2 has become a promising therapeutic target for cancer treatment. In recent years, insights into the structures of the CDK2 catalytic site and allosteric pockets have provided notable opportunities for developing more effective clinical candidates of CDK2 inhibitors. Area Covered: This article reviews the latest CDK2 inhibitors that have entered clinical trials and discusses the design and discovery of the most promising new preclinical CDK2 inhibitors in recent years. Additionally, it summarizes the development of allosteric CDK2 inhibitors and CDK2-targeting PROTACs. The review encompasses strategies for inhibitor and PROTAC design, structure-activity relationships, as well as in vitro and in vivo biological assessments. Expert Opinion: Despite considerable effort, no CDK2 inhibitor has yet received FDA approval for marketing due to poor selectivity and observed toxicity in clinical settings. Future research must prioritize the optimization of the selectivity, potency, and pharmacokinetics of CDK2 inhibitors and PROTACs. Moreover, exploring combination therapies incorporating CDK2 inhibitors with other targeted agents, or the design of multi-target inhibitors, presents significant promise for advancing cancer treatment strategies.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu